Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: Clues for the pathogenesis

Gianfranco Ferraccioli, Barbara Tolusso, Francesca Bobbio-Pallavicini, Elisa Gremese, Viviana Ravagnani, Maurizio Benucci, Edoardo Podestà, Fabiola Atzeni, Alice Mannocci, Domenico Biasi, Mariangela Manfredi, Piercarlo Sarzi-Puttini, Bruno Laganà, Carlomaurizio Montecucco

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To find out whether a high number of auto-antibodies can increase the probability of a "good-EULAR response" and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels

Original languageEnglish
Article numbere40362
JournalPLoS One
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 30 2012

Fingerprint

rheumatoid arthritis
Biomarkers
Cell- and Tissue-Based Therapy
Immunoglobulin A
B-lymphocytes
Immunoglobulin M
biomarkers
Rheumatoid Arthritis
B-Lymphocytes
pathogenesis
Cells
therapeutics
autoantibodies
Lymphocytes
Regression analysis
Autoantibodies
Logistics
Interleukin-6
Immunoglobulin G
Steroids

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients : Clues for the pathogenesis. / Ferraccioli, Gianfranco; Tolusso, Barbara; Bobbio-Pallavicini, Francesca; Gremese, Elisa; Ravagnani, Viviana; Benucci, Maurizio; Podestà, Edoardo; Atzeni, Fabiola; Mannocci, Alice; Biasi, Domenico; Manfredi, Mariangela; Sarzi-Puttini, Piercarlo; Laganà, Bruno; Montecucco, Carlomaurizio.

In: PLoS One, Vol. 7, No. 7, e40362, 30.07.2012.

Research output: Contribution to journalArticle

Ferraccioli, G, Tolusso, B, Bobbio-Pallavicini, F, Gremese, E, Ravagnani, V, Benucci, M, Podestà, E, Atzeni, F, Mannocci, A, Biasi, D, Manfredi, M, Sarzi-Puttini, P, Laganà, B & Montecucco, C 2012, 'Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: Clues for the pathogenesis', PLoS One, vol. 7, no. 7, e40362. https://doi.org/10.1371/journal.pone.0040362
Ferraccioli, Gianfranco ; Tolusso, Barbara ; Bobbio-Pallavicini, Francesca ; Gremese, Elisa ; Ravagnani, Viviana ; Benucci, Maurizio ; Podestà, Edoardo ; Atzeni, Fabiola ; Mannocci, Alice ; Biasi, Domenico ; Manfredi, Mariangela ; Sarzi-Puttini, Piercarlo ; Laganà, Bruno ; Montecucco, Carlomaurizio. / Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients : Clues for the pathogenesis. In: PLoS One. 2012 ; Vol. 7, No. 7.
@article{16faeec00a184b9d98f6356ac1a9fd1a,
title = "Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: Clues for the pathogenesis",
abstract = "Objective: To find out whether a high number of auto-antibodies can increase the probability of a {"}good-EULAR response{"} and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75{\%} non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9{\%}) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels",
author = "Gianfranco Ferraccioli and Barbara Tolusso and Francesca Bobbio-Pallavicini and Elisa Gremese and Viviana Ravagnani and Maurizio Benucci and Edoardo Podest{\`a} and Fabiola Atzeni and Alice Mannocci and Domenico Biasi and Mariangela Manfredi and Piercarlo Sarzi-Puttini and Bruno Lagan{\`a} and Carlomaurizio Montecucco",
year = "2012",
month = "7",
day = "30",
doi = "10.1371/journal.pone.0040362",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients

T2 - Clues for the pathogenesis

AU - Ferraccioli, Gianfranco

AU - Tolusso, Barbara

AU - Bobbio-Pallavicini, Francesca

AU - Gremese, Elisa

AU - Ravagnani, Viviana

AU - Benucci, Maurizio

AU - Podestà, Edoardo

AU - Atzeni, Fabiola

AU - Mannocci, Alice

AU - Biasi, Domenico

AU - Manfredi, Mariangela

AU - Sarzi-Puttini, Piercarlo

AU - Laganà, Bruno

AU - Montecucco, Carlomaurizio

PY - 2012/7/30

Y1 - 2012/7/30

N2 - Objective: To find out whether a high number of auto-antibodies can increase the probability of a "good-EULAR response" and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels

AB - Objective: To find out whether a high number of auto-antibodies can increase the probability of a "good-EULAR response" and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels

UR - http://www.scopus.com/inward/record.url?scp=84864467675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864467675&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0040362

DO - 10.1371/journal.pone.0040362

M3 - Article

C2 - 22859946

AN - SCOPUS:84864467675

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e40362

ER -